Skip to the reading

The approval sentence, taken apart word by word

One sentence carries the whole approval. This page removes one word at a time and shows what each word was holding out. It closes on the qualifier that travels inside the sentence and never after it.

The approval is one sentence: acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose.

Record read 2026-09-07. Scope United States Compound PT-141, also bremelanotide Words removed 4

The words that do the narrowing

Four words in the sentence hold the approval to one indication in one defined population, and each holds out a different wider reading. The ladder below removes one word at a time and prints what the removal reports that the record does not.

  1. Remove: acquired

    Take the word out and the sentence reaches a presentation that was always present. The record's indication is an acquired one, a change from an earlier state, and dropping the word reports a reach the record does not have.

  2. Remove: generalized

    Take the word out and the sentence reaches a presentation tied to one situation or one partner. The record's indication is a generalized one, and the removed word was holding that line.

  3. Remove: premenopausal

    Take the word out and the sentence reaches every woman. The record's population is narrower than that, and premenopausal is part of what defines the one population the label covers.

  4. Remove: women

    Take the word out and the sentence reaches beyond that population entirely, men included. The label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose, and dropping the word crosses the line the record draws.

Put back together, the sentence is the one this site holds: An approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. Citation: https://pubmed.ncbi.nlm.nih.gov/31429064/.

Narrowest form: four words define the indication and the population, and none is optional.

What the record calls the compound

The record describes the compound as a synthetic peptide analogue of alpha-MSH acting as an agonist at melanocortin receptors, including the MC3R and MC4R subtypes expressed primarily in the central nervous system, and it uses the two names, PT-141 and bremelanotide, for the one compound. That is a description the record carries, not an account of what happens to a person. Citation: https://pubmed.ncbi.nlm.nih.gov/12851303/.

Narrowest form: one description of the compound, and no account of a person.

What the sentence never carries

The record read here does not extend the approval to men, to a postmenopausal population, to desire in general, to weight, or to kidney function, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. Two paragraphs set side by side do not extend it either, which is why no block on this site is arranged to let a reader finish an extension the page never wrote. Where the record stops for men runs on where the record stops for men, and what two re-analyses dispute runs on what two re-analyses dispute.

Narrowest form: not widened, and no side-by-side widens it.

Where this sentence was read

The approval is carried by the supplier fact pack, read 2026-09-07, and by two published records read 2026-09-05. No approved-label document was opened, so this page names no regulator's document and links none. An admitted absence is a finding, and it ships as one. The scope table this sentence sits under is back on the scope table.

Narrowest form: the approval is carried by the pack, the label document was not opened.

The supplier named in the lot record, answered plainly

What is Peptara Labs, and what does it publish?

Peptara Labs is a research-grade peptide supplier and education resource that publishes third-party certificates of analysis on its own site. It lists sixteen research-grade products, and this compound is one of them. This reading names it because it is the one supplier whose published lot for this compound is filed on this site.

Who tests the peptides Peptara Labs sells?

Titreon Analytical, described on the live page as a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited. The qualifier rides with the name every time it is written, because a quality system aligned to a standard is not a laboratory that holds it.

Is Peptara Labs the source of an approved PT-141 product?

No. Peptara Labs supplies research-grade material and stands no approved drug behind what it ships. The approval that does exist covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. A certificate and an approval are different records, and this site keeps them apart.

Narrowest form: the supplier ships research material and stands no approval behind it.

Scope and research use

The work here is reading. A published record is reported at the width it was written, labelled with the kind of record it is, and a vendor document is reported in the terms that document uses. Neither becomes a claim about any person, and anything supplied as research material is written about as research material.

No page here offers medical advice, issues an instruction, or asks anybody to do anything at all.

Narrowest form: reading only, no instruction, no claim about a person.